Speciality: Oncology
Description:
A warm welcome to all the medical professionals joining us for this insightful session on the multifaceted advantages of CDK4/6 Inhibitors in HR+/HER2- Advanced Breast Cancer Clinical Studies. The landscape of advanced breast cancer treatment has been profoundly reshaped by the advent of CDK4/6 inhibitors. These targeted therapies, including palbociclib, ribociclib, and abemaciclib, have revolutionized the management of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer, demonstrating significant improvements in progression-free and overall survival rates compared to traditional endocrine therapy alone. Their mechanism of action, by selectively inhibiting cyclin-dependent kinases 4 and 6, effectively halts cell cycle progression and offers a more precise approach to combating cancer.
Dr. Bhavna Parikh, a distinguished expert in the field, will delve into the compelling clinical evidence supporting the widespread adoption of these agents. Through landmark clinical trials, CDK4/6 inhibitors have consistently shown superior efficacy, extending the time patients live without disease progression and enhancing their quality of life. This session will explore the nuances of these studies, highlighting the patient populations who benefit most, the optimal sequencing strategies, and the management of potential side effects, ensuring a comprehensive understanding of their practical application in clinical settings.
The integration of CDK4/6 inhibitors into the treatment paradigm for HR+/HER2- advanced breast cancer represents a monumental leap forward in personalized oncology. This webinar is an invaluable opportunity to gain an overall knowledge of the best practices and latest advancements in leveraging these inhibitors for improved patient outcomes. Don't miss this chance to grab the shared knowledge and follow Hidoc for more such interesting webinar sessions that keep you at the forefront of medical innovation.
See More Webinars @ Hidoc Webinars
1.
"Unusual" Cancers Following Pandemic; Triumph in TNBC; Clinical Trial Interrupted by Shortage.
2.
Recently released national data on drug use and abuse among Americans.
3.
Despite Medicare Coverage, Cancer Genomic Testing Still Low
4.
Ketamine plus psychotherapy for "excellent" PTSD
5.
Psychedelic Therapy Tied to Reduced Depression, Anxiety.
1.
Personalized Tumor Ecological Landscapes in Oncology
2.
Unlocking the Potential of Glofitamab: A Novel Treatment for Cancer
3.
Preserving Social Identity During Cancer Survivorship
4.
Battling Blood Cancers: Advances in HIV-Related Hematologic Malignancies in the ART Era
5.
Regenerative Models of Tumor Microenvironments: Clinical Relevance and Emerging Insights
1.
International Conference on Cancer Nursing and Rehabilitation Strategies
2.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
3.
International Conference on Innovations in Critical Care for Oncology and Cardiology
4.
International Symposium on Oncology, Cardiology and Critical Care Innovations
5.
International Conference on Cancer Nursing and Hematology Support
1.
An Intro to The Multifaceted Advantages of CDK4/6 Inhibitors in HR+/HER2- Advanced Breast Cancer Clinical Studies.
2.
Dacomitinib Case Presentation: Baseline Treatment and Current Status
3.
Advances in Classification/ Risk Stratification of Plasma Cell Dyscrasias- The Summary
4.
From Guidelines to Practice: Hematology
5.
Breast Cancer Awareness and Early Detection
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation